• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Update on multikinase inhibitor therapy for differentiated thyroid cancer
【24h】

Update on multikinase inhibitor therapy for differentiated thyroid cancer

机译：多喹术抑制剂治疗分化甲状腺癌的疗法更新

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Curative therapies for radioiodine-refractory differentiated thyroid cancer remain lacking. However, oral multikinase inhibitors often allow for disease control and improved progression-free survival. Two agents, lenvatinib and sorafenib, have been approved for radioiodine-refractory differentiated thyroid cancer on the basis of phase III clinical trials showing marked response rates and improved progression-free survival over placebo. Several other multikinase inhibitors, including apatinib, axitinib, cabozantinib, pazopanib, sunitinib and vandetanib, have also been studied in phase II clinical trials, with varying response rates and comparable progression-free survival. Selective kinase inhibitors, including dabrafenib, vemurafenib, selumetinib and gefitinib, offer a more targeted approach and have also been studied in phase II clinical trials. While the emergence of these treatments has changed the landscape of management of advanced thyroid cancer, clinical challenges remain, and there are many areas of ongoing research.
机译：放射性碘 - 难治性分化的甲状腺癌的疗法仍然缺乏。然而，口服多立糖酶抑制剂通常允许疾病控制和改善无进展的存活。在第III期临床试验的基础上，已经批准了两种药剂，Lenvatinib和Sorafenib，批准了放射性碘 - 难治性分化的甲状腺癌，显示出明显的反应率和改善安慰剂的无进展生存率。在II期临床试验中还研究了几种其他多立糖酶抑制剂，包括磷钛，Axitinib，Cabozantib，Pazopanib，Sunitinib和Vandetanib，具有不同的响应率和可比性的无疾病存活率。选择性激酶抑制剂，包括Dabrafenib，Vemurafenib，Selumetinib和Gefitinib，提供更具靶向方法，并在II期临床试验中进行了研究。虽然这些治疗的出现改变了先进甲状腺癌的管理景观，但仍然存在临床挑战，并且有许多正在进行的研究领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号